Body weight and adiposity models: In diet-induced obesity (DIO) mouse models, retatrutide demonstrated pronounced effects on body weight trajectories over multi-week observation periods compared with vehicle controls
GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients
Eli Lilly, the pharmaceutical company behind Retatrutide, has invested in a massive clinical trial program
The art of tissue-specific and disease-specific dosing may emerge in the not-too-distant future: Rather than using the current pharmacologic doses of GLP-1s to soak receptors throughout the body, we may learn how to apply much more tailored brush strokes to effectively treat, say, dementia or rheumatoid arthritis
At Refine by Tulsi, Dr Kotecha has been working with numerous patients to develop a personalized, science-backed weaning protocols to help patients maintain their weight loss while gradually reducing reliance and cost associated with GLP-1s
Pricing subject to change without notice